A detailed history of Paradigm Financial Partners, LLC transactions in Abb Vie Inc. stock. As of the latest transaction made, Paradigm Financial Partners, LLC holds 11,005 shares of ABBV stock, worth $2.12 Million. This represents 0.29% of its overall portfolio holdings.

Number of Shares
11,005
Previous 6,688 64.55%
Holding current value
$2.12 Million
Previous $1.22 Million 55.05%
% of portfolio
0.29%
Previous 0.26%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 13, 2024

BUY
$154.79 - $180.76 $668,228 - $780,340
4,317 Added 64.55%
11,005 $1.89 Million
Q1 2024

May 15, 2024

SELL
$159.82 - $182.1 $20,616 - $23,490
-129 Reduced 1.89%
6,688 $1.22 Million
Q4 2023

Feb 05, 2024

BUY
$137.6 - $154.97 $16,512 - $18,596
120 Added 1.79%
6,817 $1.06 Million
Q3 2023

Oct 12, 2023

BUY
$133.59 - $154.65 $59,180 - $68,509
443 Added 7.08%
6,697 $998,000
Q2 2023

Jul 13, 2023

BUY
$132.51 - $164.9 $14,841 - $18,468
112 Added 1.82%
6,254 $842,000
Q1 2023

Apr 11, 2023

BUY
$144.61 - $166.54 $630,933 - $726,614
4,363 Added 245.25%
6,142 $978,000
Q4 2022

Jan 27, 2023

SELL
$138.31 - $165.87 $276 - $331
-2 Reduced 0.11%
1,779 $0
Q3 2022

Nov 09, 2022

SELL
$134.21 - $153.93 $30,063 - $34,480
-224 Reduced 11.17%
1,781 $250,000
Q2 2022

Jul 27, 2022

SELL
$137.62 - $174.96 $253,496 - $322,276
-1,842 Reduced 47.88%
2,005 $305,000
Q1 2022

May 16, 2022

BUY
$131.98 - $163.75 $66,385 - $82,366
503 Added 15.04%
3,847 $650,000
Q4 2021

Feb 18, 2022

SELL
$107.43 - $135.93 $2.37 Million - $3 Million
-22,082 Reduced 86.85%
3,344 $453,000
Q4 2021

Feb 10, 2022

BUY
$107.43 - $135.93 $2.43 Million - $3.07 Million
22,581 Added 793.71%
25,426 $3.44 Million
Q3 2021

Nov 15, 2021

BUY
$106.4 - $120.78 $11,597 - $13,165
109 Added 3.98%
2,845 $315,000
Q2 2021

Aug 12, 2021

BUY
$105.21 - $117.21 $287,854 - $320,686
2,736 New
2,736 $308,000

Others Institutions Holding ABBV

About AbbVie Inc.


  • Ticker ABBV
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 1,768,099,968
  • Market Cap $341B
  • Description
  • AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheuma...
More about ABBV
Track This Portfolio

Track Paradigm Financial Partners, LLC Portfolio

Follow Paradigm Financial Partners, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Paradigm Financial Partners, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Paradigm Financial Partners, LLC with notifications on news.